Key Inclusions
§ A
detailed assessment of the current market landscape of approved antibiotic
generics, including information on drug developers, year of approval, region(s)
of approval, type of antibiotic (based on chemical structure and drug class),
mechanism of action (alteration of cell membranes, cell wall synthesis
inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis
inhibition, protein synthesis inhibition and RNA polymerase inhibition),
spectrum of activity (broad spectrum, extended spectrum and narrow spectrum),
type of target bacteria (gram negative and gram positive), target bacterial
strain(s), target diseases indication(s), nature of source (semi-synthetic and
synthetic), type of therapy (combination therapy and monotherapy), route(s) of
administration (intramuscular, intravenous, oral, topical and others /
unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and
others), and type of patient population (based on age and gender).
§ A
detailed assessment of the current market landscape of approved antibiotic brands,
including information on drug developers, year of approval, region(s) of
approval, type of antibiotic (based on chemical structure and drug class),
mechanism of action (alteration of cell membranes, cell wall synthesis
inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis
inhibition, protein synthesis inhibition and RNA polymerase inhibition),
spectrum of activity (broad spectrum, extended spectrum and narrow spectrum),
type of target bacteria (gram negative and gram positive), target bacterial
strain(s), target diseases indication(s), nature of source (semi-synthetic and
synthetic), type of therapy (combination therapy and monotherapy), route(s) of
administration (intramuscular, intravenous, oral, topical and others /
unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and
others), type of patient population (based on age and gender) and type of
innovation.
§ A detailed assessment of the overall
market landscape of clinical-stage antibiotics, including information on drug
developers, status of development (clinical and preclinical), stage of
development, type of antibiotic (based on chemical structure and drug class),
mechanism of action (cell membrane alteration, cell wall synthesis inhibition,
FABI inhibition, fatty acid synthesis inhibition, nucleic acid synthesis
inhibition, protein synthesis inhibition and others), spectrum of activity
(broad spectrum, extended spectrum and narrow spectrum), type of target
bacteria (gram negative and gram positive), target bacterial strain(s), target
disease indication(s), therapeutic area(s) (genetic disorder, immunological
disorder, infectious disease, oncological disorder, renal disorder and sexually
transmitted disease), nature of source (semi-synthetic and synthetic), type of
therapy (combination therapy and monotherapy), route(s) of administration
(intramuscular, intravenous, oral and others / unspecified), dosage form(s)
(capsules, liquids, tablets and others / unspecified), dosage strength, dosage
frequency, dosing period, type of patient population (based on age and gender).
§ Elaborate profiles of key players
engaged in the development of antibiotics (shortlisted based on proprietary
criterion), including a brief overview of the company, key executives,
financial information (if available), product portfolio, recent developments
and an informed future outlook. In addition, the chapter highlights the key
strategies and key focus areas of the developers, along with expert opinion.
§ A detailed analysis of partnerships
inked between stakeholders engaged in this domain, since 2017, based on several
relevant parameters, such as year of partnership, type of partnership
(acquisitions, commercialization agreements, distribution agreements, joint
development agreements, licensing agreements, manufacturing agreements, product
development agreements, product development and commercialization agreements,
research and development agreements, technology utilization agreements and
others), type of partner, company size, most active players (in terms of number
of partnerships) and regional distribution of partnership activity in this
domain.
§ A detailed analysis of completed and
ongoing clinical studies related to antibiotics, based on several relevant
parameters, such as trial registration year, trial status, trial phase, type of
patient population (based on gender), key focus areas, type of sponsor,
geography and most active industry and non-industry players (in terms of number
of trials).
§ An insightful analysis, highlighting the
key opinion leaders (KOLs) investigating clinical trials related to
antibiotics, based on several relevant parameters, such as type of KOL,
qualification, type of organization, affiliated organization, geographical
location of KOLs and target disease indication(s). In addition, the chapter
highlights the most prominent KOLs, based on our proprietary and third-party
scoring criteria.
§ An elaborate discussion on key trends
within the antibiotics industry providing insights on drug-pricing, outsourcing
trends and impact of COVID-19 on the antibiotics domain.
§ An insightful success protocol analysis
of recently approved antibiotics, based on several relevant parameters, such as
dosing frequency, drug efficacy, geographical reach, inter-class competition,
intra-class competition, innovation feature, price, prevalence, route of
administration, spectrum of activity, type of therapy and type of target
bacteria
§ Informed estimates of the existing
market size and the future opportunity for global antibiotics
market, over the next
decade. Based on multiple parameters, such as drug class, mechanism of action,
nature of source, target disease indication, type of therapy, routes of
administration and key geographical regions. We have provided informed
estimates on the evolution of the market for the period 2020-2030.
The
report also features the likely distribution of the current and forecasted
opportunity across important market segments, mentioned below:
§ Type of Drug Class
§ Tetracyclines
§ Aminoglycosides
§ Lincosamides
§ Carbapenems
§ Lipoglycopeptides
§ Cephalosporins
§ Fluoroquinolones
§ Triazaacenaphthylenes
§ Other Drug Classes
§ Mechanism of Action
§ Protein Synthesis Inhibition
§ Cell Wall Synthesis Inhibition
§ Nucleic Acid Synthesis Inhibition
§ DNA Synthesis Inhibition
§ Mycolic Acid Synthesis Inhibition
§ Nature of Source
§ Semi-synthetic
§ Synthetic
§ Target Disease Indication
§ Respiratory Tract Infections
§ Dermatological Infections
§ Urinary Tract Infections
§ Sexually Transmitted Infections
§ Gastrointestinal Infections
§ Hematological Infections
§ Ear Infections
§ Cystitis
§ Diabetic Foot Infections
§ Other Bacterial Infections
§ Type of Therapy
§ Monotherapies
§ Combination Therapies
§ Route of Administration
§ Intravenous
§ Oral
§ Intravenous / Oral
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
§ MENA
§ Latin America
Key Questions Answered
§ Who
are the leading players involved in the development of antibiotics?
§ Which
popular therapeutic areas are being targeted by clinical-stage antibiotics?
§ What
is the focus area of the ongoing research activity in the antibiotics domain?
§ What types of partnership models are
commonly adopted by stakeholders in this industry?
§ What
are the crucial factors that impact the sales of antibiotics?
§ Who
are the major key opinion leaders in the antibiotics domain?
§ What are the key market trends and
driving factors that are likely to impact this market?
§ What is the current / likely future
global antibiotics
market size?
§ Which drug class accounts for the largest
share within the antibiotics market?
§ Which region captures the largest share
of the antibiotic
market?
To
view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/global-antibiotics-market.html
Learn
from experts: do you know about these
emerging industry trends?
Introduction To
Exosome Therapeutics
Unlocking the Potential
of Digital Twins in Healthcare: Benefits, Challenges and Opportunities
Learn from our recently published
whitepaper: -
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the
pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
Learn more about Roots
Analysis consulting services:
Roots Analysis Consulting - the
preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415